Literature DB >> 17489943

Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis.

M Terzi1, A Birinci, E Cetinkaya, M K Onar.   

Abstract

BACKGROUND: Tau protein is present in the microtubules of axons. Markers of various types have been used to demonstrate multiple sclerosis (MS) activity and axonal damage. This study aimed to demonstrate the association between cerebrospinal fluid (CSF) tau protein concentrations and clinical prognosis in MS patients.
METHODS: We included 45 patients that were diagnosed according to the McDonald's criteria. The control group was made up of 38 patients that had no signs or symptoms related to the primary central nervous system lesion correlated with the patient group. CSF total tau protein was measured using the ELISA method based on the sandwich method with Innogenetics Innotest hTau antigen kit in pg/ml type.
RESULTS: In the patient group, the mean CSF total tau protein level was 238.66 +/- 237.44, whereas it was 93.65 +/- 82.14 in the control group. The mean total tau protein was higher in the three clinical forms when compared with the control group and it was statistically significant (P<0.05).
CONCLUSIONS: High tau protein level may be an early marker of axonal damage and this marker may be used for monitoring axon preventing therapies in the follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17489943     DOI: 10.1111/j.1600-0404.2007.00782.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

Review 1.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 2.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 3.  Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Authors:  Amit Bar-Or; Peter Rieckmann; Anthony Traboulsee; V Wee Yong
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 4.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.

Authors:  Jacek Jaworski; Marek Psujek; Marzena Janczarek; Małgorzata Szczerbo-Trojanowska; Halina Bartosik-Psujek
Journal:  Ups J Med Sci       Date:  2012-05-04       Impact factor: 2.384

6.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

Review 7.  Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

Authors:  Alberto Gajofatto; Matilde Bongianni; Gianluigi Zanusso; Maria Donata Benedetti; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

8.  Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis.

Authors:  Lenka Fialová; Ales Bartos; Jana Svarcová; Ivan Malbohan
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

Review 9.  Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

Authors:  Ahmed Abdelhak; Andreas Junker; Johannes Brettschneider; Jan Kassubek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

Review 10.  Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Authors:  Alberto Gajofatto; Massimiliano Calabrese; Maria Donata Benedetti; Salvatore Monaco
Journal:  Dis Markers       Date:  2013-11-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.